Abstract
Importance Older patients and those with underlying comorbidities infected with SARS-CoV-2 may be at increased risk of hospitalization and death from COVID-19. Sotrovimab is a neutralizing antibody designed for treatment of high-risk patients to prevent COVID-19 progression.
Objective To evaluate the efficacy and safety of sotrovimab in preventing progression of mild to moderate COVID-19 to severe disease.
Design Randomized, double-blind, multicenter, placebo-controlled, phase 3 study.
Setting 57 centers in 5 countries.
Participants Nonhospitalized patients with symptomatic, mild to moderate COVID-19 and at least 1 risk factor for disease progression.
Intervention Patients were randomized (1:1) to an intravenous infusion of sotrovimab 500 mg or placebo.
Main Outcomes and Measures The primary efficacy outcome was the proportion of patients with COVID-19 progression, defined as all-cause hospitalization longer than 24 hours for acute illness management or death through day 29. Key secondary outcomes included the proportion of patients with COVID-19 progression, defined as emergency room visit, hospitalization of any duration, or death, and proportion of patients developing severe/critical respiratory COVID-19 requiring supplemental oxygen.
Results Among 1057 patients randomized (sotrovimab, 528; placebo, 529), all-cause hospitalization longer than 24 hours or death was significantly reduced with sotrovimab (6/528 [1%]) vs placebo (30/529 [6%]) by 79% (95% CI, 50% to 91%; P<.001). Secondary outcome results further demonstrated the effect of sotrovimab in reducing emergency room visits, hospitalization of any duration, or death, which was reduced by 66% (95% CI, 37% to 81%; P<.001), and severe/critical respiratory COVID-19, which was reduced by 74% (95% CI, 41% to 88%; P=.002). No patients receiving sotrovimab required high-flow oxygen, oxygen via nonrebreather mask, or mechanical ventilation compared with 14 patients receiving placebo. The proportion of patients reporting adverse events was similar between treatment groups; sotrovimab was well tolerated, and no safety concerns were identified.
Conclusions and Relevance Among nonhospitalized patients with mild to moderate COVID-19, a single 500-mg intravenous dose of sotrovimab prevented progression of COVID-19, with a reduction in hospitalization and need for supplemental oxygen. Sotrovimab is a well-tolerated, effective treatment option for patients at high risk for severe morbidity and mortality from COVID-19.
Trial Registration ClinicalTrials.gov Identifier: NCT04545060
Competing Interest Statement
Drs Gupta, Gonzalez-Rojas, Juarez, Crespo Casal, Moya, Solis, and Shapiro report acting as trial investigators for Vir Biotechnology and receiving non-financial support from Vir Biotechnology during the conduct of the study. Dr Rodrigues Falci reports acting as a trial investigator for Vir Biotechnology and receiving nonfinancial support from Vir Biotechnology during the conduct of the study, and personal fees and nonfinancial support from Pfizer and United Medical, nonfinancial support from Gilead Sciences and Merck Sharp & Dohme, and personal fees from GlaxoSmithKline outside the submitted work. Dr Sarkis reports acting as a trial investigator for Vir Biotechnology and receiving nonfinancial support from Vir Biotechnology during the conduct of the study; research support from AbbVie, Eli Lilly, GlaxoSmithKline, Otsuka, Vir Biotechnology, Eisai, and Ironshore; and serving on speaker bureaus for Janssen, Teva, and AbbVie. Drs Zheng, Parra, Sager, Alexander, Yeh, and Aldinger are employees of Vir Biotechnology and report stock ownership in Vir Biotechnology and third-party funding from GlaxoSmithKline to Vir Biotechnology for the submitted work. Ms Scott, Dr Austin, and Dr Peppercorn are employees of GlaxoSmithKline and report stock ownership in GlaxoSmithKline. Dr Cathcart is an employee of Vir Biotechnology and reports stock ownership in Vir Biotechnology, third-party funding from GlaxoSmithKline to Vir Biotechnology for the submitted work, and stock ownership in Gilead Sciences outside the submitted work. Dr Brinson reports acting as a trial investigator for Vir Biotechnology and receiving nonfinancial support from Vir Biotechnology during the conduct of the study, and personal fees for advisory boards and speakers bureaus from Gilead Sciences and ViiV Healthcare outside the submitted work.
Clinical Trial
NCT04545060
Funding Statement
This study was sponsored by Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the following ethics review boards: Research Ethical Committee of the Universidade De Passo Fundo/Office Of The Assistant Dean Of Research And Graduate Studies, Brazil (454545/249305), Research Ethical Committee of the Liga Norte Riograndense Contra O Cancer, Brazil (356987/249067), Comite de Etica em Pesquisa do Hospital Leforte, Brazil (454407/249306; 454407/249306), Research ethical Committee of the Hospital de Clinicas de Porto Alegre of the Federal University of Rio Grande do Sul, Brazil (412641/249076), Research Ethical Committee of the Brotherhood of the Holy House of Mercy of Porto Alegre, Brazil (452132/249278), Advarra, Canada (125285/249219; 233252/249074), Comite Nacional Transitorio de Etica en Investigacion para la evaluacion y supervision eticas de los Ensayos Clinicos de la enfermedad COVID-19 (CNTEI COVID-19), Peru (453319/249281), CEIm Corporacio Sanitaria Parc Tauli Parque del Tauli, Spain (466003/249291; 010074/249923; 230601/249242), Advarra, United States (316647/249611; 393090/249560; 320687/249555; 427380/249631; 093073/249546; 449583/248364; 009334/249320; 021490/248894; 457707/249681; 076115/248362; 457712/249682; 354044/249803; 171466/248900; 458530/249910; 457765/249683; 408728/249251; 458692/249844; 176292/249239; 006879/248345; 347052/249553; 455576/249387; 455582/249389; 456034/249493; 053521/249195; 455575/249386; 028996/249554; 458529/249909; 370717/249241; 331745/249072; 453800/249220; 459369/249998; 429263/248346; 455578/249390; 457328/249637; 259973/249632; 023446/249253; 457766/249684; 456703/249634; 014897/248899; 306670/249073; 306670/249073; 007907/250048; 373940/248347; 419336/249556; 455826/249420.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will serve as a basis for a regulatory filing and cannot be shared at this time.
